NasdaqGS:RXRXBiotechs
New Recursion CMO Puts Oncology Experience At Center Of Investor Focus
Recursion Pharmaceuticals (NasdaqGS:RXRX) has appointed Vicki Goodman, M.D., as Chief Medical Officer, effective April 6, 2026.
Dr. Goodman succeeds David Mauro, M.D., Ph.D., and brings more than 20 years of oncology drug development leadership.
Her background includes senior roles at Mural Oncology, Exelixis, Merck, Bristol Myers Squibb, and GlaxoSmithKline, with experience on major oncology products such as KEYTRUDA, OPDIVO, and YERVOY.
For investors tracking Recursion Pharmaceuticals at...